Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Benzocaine
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Anbesol, Lanacane, Orajel, others |
| AHFS/Drugs.com | Monograph |
| Routes of administration | Topical, Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.002.094 |
| Chemical and physical data | |
| Formula | C9H11NO2 |
| Molar mass | 165.192 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Benzocaine, sold under the brand name Orajel amongst others, is a local anesthetic, belonging to the amino ester drug class, commonly used as a topical painkiller or in cough drops. It is the active ingredient in many over-the-counter anesthetic ointments such as products for oral ulcers. It is combined with antipyrine to form A/B ear drops. In the US, products containing benzocaine for oral application are contraindicated in children younger than two years old.[1] In the European Union, the contraindication applies to children under 12 years of age.[medical citation needed]
It was first synthesised in 1890 in Germany and approved for medical use in 1902.[2]
- ^ "Safety Alerts for Human Medical Products - Oral Over-the-Counter Benzocaine Products: Drug Safety Communication - Risk of Serious and Potentially Fatal Blood Disorder". www.fda.gov. Archived from the original on September 7, 2018. Retrieved May 26, 2018.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 475. ISBN 9783527607495.
Previous Page Next Page
